Altered brain activity and functional connectivity after MDMA-assisted therapy for post-traumatic stress disorder.
Frontiers in Psychiatry 2022 S Parker Singleton, Julie B. Wang, Michael C Mithoefer et al. 36 citations
3,4-methylenedioxymethamphetamine-assisted therapy (MDMA-AT) for post-traumatic stress disorder (PTSD) has demonstrated promise in multiple clinical trials. MDMA is hypothesized to facilitate the therapeutic process, in part, by decreasing fear response during fear memory processing while increasing extinction learning. The acute administration of MDMA in healthy controls modifies recruitment...